Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology
MONTPELLIER, France–(BUSINESS WIRE)–Teva Pharmaceuticals has notified MedinCell (Paris:MEDCL) that it made the decision to initiate the clinical Phase 3 trial for mdc‑TJK. MedinCell will receive immediately a $3 million payment from Teva Pharmaceuticals linked to the project development milestone. The Phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting … [Read more…]
